Mabtech turned to Qamcom Research and Technology – a world-class centre of excellence for R&D partnerships – who took on full project responsibility.
A joint project team was established. Combining Mabtech’s knowledge of biological applications and researchers’ needs of additional software features, with Qamcom’s expertise in signal processing and embedded systems, the team refined the algorithm for commercial deployment. This came to life as their new RAWspot™ technology.
Simultaneously, Qamcom designed and built an entirely new spot reader, able to take full advantage of RAWspot’s capabilities and of achieving the goal of truly reinventing spot analysis. This included every element of the hardware, firmware, software and user interface design, taking the project all the way from concept to serial production.
The result was Mabtech IRIS™, a next-generation, 4-colour FluoroSpot and ELISpot reader that was capable of accurately identifying not only the number of spots but their volumes too – a world first. Fully plug-and-play, IRIS’ innovative hardware and user-friendly software require absolutely no calibration and vastly reduce the need for experienced users. Simply load a 96-well plate and press “Read” for completely objective results. Advanced data export functionality also significantly reduces the amount of work required for data processing from hours to minutes, thus returning valuable time to researchers.
In order to take full advantage of the power and accuracy of the RAWspot technology, the Qamcom team created Mabtech Apex™ software. Designed by Qamcom and Mabtech’s application specialists, Apex is fast and easy to use, automatically optimising all of IRIS’ settings. And with its selfcalibrating XY table, IRIS not only delivers the industry’s most accurate results, it is also the simplest reader to use on the market today.
Designed for scientists, by scientists, Mabtech IRIS is truly cutting-edge technology and has instantly created exciting new possibilities for the research community. In fact, as soon as it was launched, IRIS was immediately put to use by researchers around the world, including projects as diverse as researching malaria immunity in Kenya, cancer in Germany and child diabetes in the UK.